Enfuvirtide binding domain is highly conserved in non-B HIV type 1 strains from Cameroon, West Central Africa

AIDS Research and Human Retroviruses

Volumn 21, Issue 5, 2005, Pages 430-433

  Aghokeng, Avelin Fobang ^a,b   Ewane, Léonard ^a   Awazi, Bih ^a   Nanfack, Aubin ^a   Delaporte, Eric ^b   Zekeng, Léopold ^a   Peeters, Martine ^b,c  

^a Laboratoire de Sante Hygiene Mobile   (Cameroon)

^b UNIVERSITÉ DE MONTPELLIER   (France)

^c INSTITUT DE RECHERCHE POUR LE DÉVELOPPEMENT   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; ENFUVIRTIDE; GLYCOPROTEIN;

AMINO ACID SUBSTITUTION; ARTICLE; CAMEROON; CENTRAL AFRICA; CODON; DRUG BINDING; DRUG BINDING SITE; DRUG RESISTANCE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 SUBTYPE A; HUMAN IMMUNODEFICIENCY VIRUS 1 SUBTYPE B; HUMAN IMMUNODEFICIENCY VIRUS 1 SUBTYPE CRF01 AE; HUMAN IMMUNODEFICIENCY VIRUS 1 SUBTYPE CRF02 AG; HUMAN IMMUNODEFICIENCY VIRUS 1 SUBTYPE CRF06 CPX; HUMAN IMMUNODEFICIENCY VIRUS 1 SUBTYPE CRF11 CPX; HUMAN IMMUNODEFICIENCY VIRUS 1 SUBTYPE D; HUMAN IMMUNODEFICIENCY VIRUS 1 SUBTYPE F2; HUMAN IMMUNODEFICIENCY VIRUS 1 SUBTYPE G; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN MOTIF; STRAIN DIFFERENCE; UNINDEXED SEQUENCE; VIRUS STRAIN;

AMINO ACID SEQUENCE; CAMEROON; CONSERVED SEQUENCE; HIV ENVELOPE PROTEIN GP41; HIV FUSION INHIBITORS; HIV INFECTIONS; HIV-1; HUMANS; MOLECULAR SEQUENCE DATA; PEPTIDE FRAGMENTS; RECOMBINATION, GENETIC; SEQUENCE ANALYSIS, DNA;

EID: 20444416335     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2005.21.430     Document Type: Article

References (14)

1. Cooper DA and Lange J: Peptide inhibitors of virus-cell fusion: Enfuvirtide as a case study in clinical discovery and development. Lancet Infect Dis 2004;4:426-436.
2. McCutchan FE: Understanding the genetic diversity of HIV-1. AIDS 2000;14(Suppl. 3):S31-44.
3. Kantor R and Katzenstein D: Polymorphism in HIV-1 non-subtype B protease and reverse transcriptase and its potential impact on drug susceptibility and drug resistance evolution. AIDS Rev 2003;5:25-35.
4. Xu L, Hué S, Taylor S, et al.: Minimal variation in T-20 binding domain of different HIV-1 subtypes from antiretroviral-naive and -experienced patients. AIDS 2002;16:1684-1686.
5. Roman F, Gonzalez D, Lambert C, et al.: Uncommon mutations at residue positions critical for enfuvurtide (T-20) resistance in enfuvirtide-naive patients infected with subtype B and non-B HIV-1 strains. J Acquir Immune Defic Syndr 2003;33:134-139.
6. Villahermosa ML, Perez-Alvarez L, Carmona R, et al.: Primary resistance mutations to fusion inhibitors and polymorphism in gp41 sequences of HIV-1 non-B subtypes and recombinants. AIDS 2003;17:1083-1086.
7. Cilliers T, Patience T, Pillay C, Papathanasopoullos M, and Moris L: Sensitivity of HIV-1 subtype C isolates to the entry inhibitor T-20. AIDS Res Hum Retroviruses 2004;20:477-482.
8. Hanna SL, Yang C, Owen SM, and Lal R: Resistance mutation in HIV entry inhibitors. AIDS 2002;16:1603-1608.
9. Rimsky LT, Shugars DC, and Matthews TJ: Determinants of human immunodeficiency virus type 1 resistance to gp41-derived fusion inhibitor T-20 monotherapy. J Virol 1998;72:986-993.
10. Vergne L, Bourgeois A, Mpoudi-Ngole E, et al.: Biological and genetic characteristics of HIV infections in Cameroon reveals dual group M and O infections and a correlation between SI-inducing phenotype of the predominant CRF02_AG variant and disease stage. Virology 2003;310(2):254-266.
11. Aghokeng A, Ewane L, Awazi B, Nanfack A, Delaporte E, Peeters M, and Zekeng L: Evaluation of four simple/rapid assays and two fourth generation ELISAs for the identification of human immunodeficiency virus infection on a serum panel representing the HIV-1 group M genetic diversity in Cameroon. J Acquir Immune Defic Syndr 2004;37(5):1632-1640.
12. Thompson JD, Higgins DG, and Gibson TJ: CLUSTAL W: Improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res 1994;22(22):4673-4680.
13. Peeters M, Toure-Kane C, and Nkengasong JN: Genetic diversity of HIV in Africa: Impact on diagnosis, treatment, vaccine development and trials. AIDS 2003;17(18):2547-2560.
14. Mink M, Greenberg ML, Mosier S, et al.: Impact of HIV-1 gp41 amino acid substitutions (positions 36-45) on susceptibility to T-20 (enfuvirtide) in vitro: Analysis of primary isolates recovered from patients during chronic enfuvirtide treatment and site-directed mutants in NL4-3 (abstract). Antivir Ther 2002;7:S17-18.